Comment on "Theranostic lipid nanocarriers for precision diagnosis and targeted therapy in pancreatic ductal adenocarcinoma".

This letter comments on a recent review of theranostic lipid nanocarriers for pancreatic ductal adenocarcinoma, identifying three areas of concern in the evidence base. First, the 211-item reference list contains multiple duplicated citations listed under separate numbers with identical content (for example, refs. 6/8, 9/21, 55/89, 106/117, 132/143), a recurring pattern suggesting that the bibliography was not fully verified before submission. Second, Table 6 cites reference markers "[639]" and "[640]" for the NanoSMART and NBTXR3 trials, numbers that exceed the 211-entry reference list and appear to be residual artifacts from a source document with a different numbering scheme. Third, the review reports that NC-6004 (a micellar cisplatin formulation) has completed a phase III trial in combination with gemcitabine but omits the trial's outcome, despite the review's broader argument for the translational viability of lipid- and micelle-based nanocarriers and its extended discussion of nab-paclitaxel as a successful precedent. Reporting this outcome, favorable or not, alongside existing precedents, would allow readers to weigh the review's central claim against the complete record of late-stage clinical testing. While the review offers a valuable catalogue of nanocarrier platforms and regulatory precedents, these issues warrant correction before the citation base is treated as fully reliable.